Withdrawal reactions to diazepam in combined imipramine/diazepam treatment of primary nonagitated depressed outpatients.
Twenty-seven outpatients who had primary nonagitated depression that had been treated for 3.5 months with imipramine were included in the study. Of these, 14 patients were given additional diazepam treatment (10 mg/day) and 13 patients got placebo. The additional medication was stopped, and withdrawal reactions were observed after two weeks. The depression scores (both global evaluation and CPRS) increased significantly in the diazepam group, without any changes in the placebo group. Eleven patients in the diazepam group and four in the placebo group reported their condition as impaired after discontinuing their additional medication. Four patients in the placebo group and none in the diazepam group reported improvement. The level of working activity decreased significantly in the diazepam group and increased in the placebo group. The serum level of imipramine decreased in the placebo group (P = 0.07), but not in the diazepam group. Serum levels of desipramine decreased significantly in both groups (P less than 0.05). Our study indicates that the discontinuation of diazepam, even when given in moderate dosage over a relatively short period of time, may cause withdrawal reactions in combined antidepressant/diazepam treatment. This may be caused by a possible tendency for the depression to become chronic. Such chronicity may be the reason for secondary dependency to diazepam.
Feet
P O
PO
Department of Clinical Psychiatry, Vestfold Central Hospital, Toensberg, Norway.
Larsen
S
S
Lillevold
P E
PE
Robak
O H
OH
D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D003891:Desipramine / Q000493:pharmacokinetics; D003975:Diazepam / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D007099:Imipramine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011897:Random Allocation; D013375:Substance Withdrawal Syndrome / Q000523:psychology*
D007099:Imipramine; D003975:Diazepam; D003891:Desipramine